SCHEMBL5923286

SCHEMBL5923286

Cc1cc(C)nc(NC(=N)Nc2ccc(Oc3ccc(Cl)cc3)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ POLB P06746 1/20 0.47
▸ LMNA P02545 2/20 0.43
▸ SCN9A Q15858 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ PCTP Q9UKL6 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ HTT P42858 3/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ RAB9A P51151 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4099597 0.92 LMNA (0.49) POLBLMNACYP1A2CASP1PCTP
SCHEMBL5923192 0.90 TSHR (0.47) ALDH1A1SMN1; SMN2POLBLMNAL3MBTL1
SCHEMBL5923278 0.89 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2POLBLMNASCN9A
SCHEMBL5923253 0.88 RAB9A (0.51) ALDH1A1SMN1; SMN2POLBLMNACYP1A2
SCHEMBL5923337 0.86 SCN9A (0.51) POLBLMNASCN9AL3MBTL1KMT2A
SCHEMBL12443467 0.85 MEN1 (0.48) SMN1; SMN2POLBLMNACYP1A2KMT2A
SCHEMBL5923518 0.84 SMN1; SMN2 (0.49) ALDH1A1SMN1; SMN2LMNASCN9AL3MBTL1
SCHEMBL4111655 0.83 LMNA (0.42) POLBLMNACYP1A2CASP1PCTP
SCHEMBL5923085 0.83 CYP1A2 (0.55) ALDH1A1SMN1; SMN2POLBLMNAL3MBTL1
SCHEMBL5923283 0.83 MAPT (0.58) ALDH1A1SMN1; SMN2POLBKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-05-11 — — US claimed
WO-2005095345-A2 HETEROARYL GUANIDINES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2005-10-13 — — WO claimed
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100225-A1 Heteroaryl guanidines; inhibitors of viral replication PIGS, GUCY1A1, GUCY1B1 ALDH1A1 535/4885SMN1; SMN2 1226/4885POLB 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback